Effect of Mannitol Dry Powder Challenge on Exhaled Nitric Oxide in Children

Juerg Barben¹, Marie-Pierre F. Strippoli², Daniel Trachsel³, Barbara Schiller¹, Juerg Hammer³, Claudia E. Kuehni²

¹ Department of Paediatric Pulmonology & Allergology, Children's Hospital, St. Gallen, Switzerland, ² Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland, ³ Department of Pulmonology and Intensive Care, University Children’s Hospital Basel, Basel, Switzerland

Abstract

Background: Fractional exhaled nitric oxide (FENO), a non-invasive marker of eosinophilic airway inflammation, is increasingly used for diagnostic and therapeutic decisions in adult and paediatric asthma. Standardized guidelines for the measurement of FENO recommend performing FENO measurements before rather than after bronchial provocation tests.

Objective: To investigate whether FENO levels decrease after a Mannitol dry powder (MDP) challenge in a clinical setting, and whether the extent of the decrease is influenced by number of MDP manoeuvres, baseline FENO, atopy and doctor diagnosed asthma.

Methods: Children aged 6–16 years, referred for possible reactive airway disease to a respiratory outpatient clinic, performed an MDP challenge (Aridol®, Pharmaxis, Australia). FENO was measured in doublets immediately before and after the challenge test using the portable NIOX MINO® device (Aerocrine, Stockholm, Sweden). We analysed the data using Kruskal-Wallis rank tests, Wilcoxon signed rank tests and multivariable linear regressions.

Results: One hundred and seven children completed both tests (mean±SD age 11.5±2.8 years). Overall, median (interquartile range) FENO decreased slightly by −2.5 ppb (−7.0, −0.5), from 18.5 ppb (10.5, 45.5) before the MDP challenge to 16.5 ppb thereafter (8.5, 40.5; p<0.001). In all participants, the change in FENO was smaller than one standard deviation of the baseline mean. The % fall in FENO was smaller in children with less MDP manoeuvres (e.g. higher bronchial responsiveness; p = 0.08) but was not influenced by levels of baseline FENO (p = 0.68), atopy (p = 0.84) or doctor diagnosed asthma (p = 0.93).

Conclusion: MDP challenge test influences FENO values but differences are small and clinically barely relevant.

Introduction

Asthma is the most common chronic disease of childhood, and its diagnosis remains clinical [1]. A diagnosis of asthma in children is usually based on history of a characteristic pattern of episodic respiratory symptoms and signs in the absence of an alternative explanation of them. In children, as in adults, tests of airflow obstruction, airway responsiveness and airway inflammation may provide support for a diagnosis of asthma [1]. The frequent finding of exercise-related airway narrowing in many children with asthma has been used as a diagnostic tool for years, especially when the diagnosis of asthma is uncertain [2]. Testing for exercise induced bronchoconstriction is not very sensitive, but highly specific for the diagnosis of pediatric asthma compared to direct bronchial provocation tests using methacholine [3].

Mannitol dry powder (MDP) is a new indirect bronchial provocation test, consisting of a hyperosmolar challenge comparable to hypertonic saline [4,5]. In children, a MDP challenge is easier, quicker to perform and better tolerated than a challenge test with hypertonic saline or methacholine, and it shows comparable accuracy for diagnosing asthma as exercise testing [6–9]. For these reasons, it is likely to become one of the standard bronchial challenge tests in clinical practice and research [10]. Fractional exhaled nitric oxide (FENO), a non-invasive marker of eosinophilic airway inflammation, is increasingly used for diagnostic and therapeutic decisions in adult and paediatric asthma [11]. Standardized guidelines for the measurement of FENO, published by the European Respiratory Society (ERS) and the American Thoracic Society (ATS) [12], recommend to perform FENO measurements before rather than after exercise testing, because both spirometry and exercise affect FENO levels.

Citation: Barben J, Strippoli M-PF, Trachsel D, Schiller B, Hammer J, et al. (2013) Effect of Mannitol Dry Powder Challenge on Exhaled Nitric Oxide in Children. PLoS ONE 8(1): e54521. doi:10.1371/journal.pone.0054521

Editor: Dominik Hartl, University of Tübingen, Germany

Received October 4, 2012; Accepted December 12, 2012; Published January 18, 2013

Copyright: © 2013 Barben et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was funded by AstraZeneca (Switzerland), the Lung Association St. Gallen and the Schmidheiny Foundation (Heerbrugg, St. Gallen). Mannitol dry powder challenge tests were provided by Pharmaxis (New South Wales, Australia). MPS was supported by the Swiss National Science Foundation (grant 3200B0–122341). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors would like to declare commercial funder AstraZeneca (Switzerland) as a competing interest. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: juerg.barben@kispisg.ch
Subjects and Study Design

We studied 107 white children (Caucasian Europeans) aged 6 to 16 years, who had been referred for possible reactive airway disease to respiratory outpatient clinics in two tertiary children’s hospitals in Switzerland (St.Gallen, Basel). Details of the study have been published elsewhere [6]. Exclusion criteria were other respiratory diseases (e.g. cystic fibrosis, primary ciliary dyskinesia) and a respiratory tract infection during the preceding four weeks.

Fractional Exhaled NO

We measured FENO in doublets immediately before and after the MDP challenge using the portable multi-gas analyzer (NIOX MINO®, Aerocrine, Sweden), in accordance with published guidelines [12] and previous studies using this device [15,16]. The portable analyzer ensures a constant expiratory flow of 50–55 ml/s, has an accuracy of ±10% with a minimum of ±5 ppb. FENO measurements from this portable analyzer correlate well with those obtained by chemiluminescence detectors [16].

Mannitol Dry Powder Challenge

The MDP challenge (Aridol®, Pharmaxis, New South Wales, Australia) was performed as described previously [5,7]. In brief, subjects were asked to inhale the contents of a MDP capsule through the delivery device (Osmohaler®). Doses were increased step-wise (0, 5, 10, 20, 40, 80, 160, 160 mg) until there was either a ≥15% fall of forced expiratory volume in 1 second (FEV₁) compared to baseline, or a 10% fall in FEV₁ between two doses. After each dose, children were instructed to perform a 5-second breath-hold, and then spirometry was performed in duplicates one minute later, and the higher FEV₁ was recorded. The results of the MDP challenge were reported as a percent decrease of FEV₁ from baseline (FEV₁ value measured after the 0-mg capsule), and the provocative dose inducing a 15% drop of FEV₁ (PD₁5) was calculated. At the end of the challenge, a short-acting beta₂-agonist was given to reverse bronchoconstriction. A negative MDP challenge, defined as no significant fall in FEV₁ after a cumulative dose of 635 mg, included eleven FEV₁ manoeuvres in doublets. BHR severity is defined as mild (<155 mg, 8–10 manoeuvres), moderate (35–155 mg, 5–7 manoeuvres) and severe (<35 mg, ≤4 manoeuvres).

Clinical Assessment

The responsible paediatric respiratory physicians made a diagnosis (asthma, or alternative diagnoses) for every child after the first visit, taking into consideration medical history, clinical examination and all conventional test results (including bronchodilator response) before MDP challenge and FENO measurement were performed.

Skin Prick Test

We performed skin prick tests (SPT) using birch, grass, mugwort, alternaria, cat, house dust mites (D. pteronyssinus) and positive and negative controls, considering a wheal of ≥3 mm as positive. These allergens cover 95% of inhaled allergies in Switzerland [17]. Atopy is defined as mild (1 to 2 positive SPT) and moderate (≥3 positive SPT).

Statistics

We analysed the data with STATA, version 11.2 (Stata Corporation, Austin, Texas). Because FENO levels were not normally distributed, we used non-parametric tests: the Kruskal-Wallis rank test to compare FENO levels between groups and the Wilcoxon signed rank test to compare FENO levels before and after MDP challenge. We assessed the association between % difference in FENO and levels of baseline FENO, doctor diagnosed asthma, atopy and BHR severity, using linear regressions.
Results

One hundred and seven children completed both tests (mean ± SD age 11.5 ± 2.8 years). Eighty nine children (83%) were sensitized to at least one allergen and 71 (66%) to two or more, 64 (60%) were diagnosed by the clinician as having asthma, and 14 (13%) were on inhaled corticosteroids (Table 1). The MDP challenge was positive (BHR severity mild to severe) in 31 children (29%). Median (interquartile range) FENO levels at baseline were higher in children diagnosed with asthma (26.0 (12.5,63.0) vs. 14.5 (8.0,22.5)), in atopic children (moderate 21.3 (12.5,56.5), mild 22.0 (12.5,49.0), none 8.0 (5.5,14.5)), and in those with a positive MDP challenge test (moderate to severe 65.0 (40.5,122.5), mild 42.5 (25.0,71.3), normal 14.0 (9.3,22.3); all \( p < 0.001 \).

Overall, median (IQR) FENO decreased by \(-2.5 \text{ ppb} (-7.0, -0.5)\), from 18.5 ppb (10.5,45.5) before the MDP challenge to 16.5 ppb thereafter (8.5,40.5; \( p < 0.001 \), Table 2). This change corresponds to a \% difference of \(-11.2\% \) (95% confidence interval \(-15.2, -7.1\); Figure 1). In 81 children (76%) FENO decreased after the MDP challenge (median difference (IQR; range) \(-3.5 \text{ ppb} (-8.5, -2.5; -27.5, -0.5)\)), in 18 (17%) children FENO levels increased (median difference 2.0 ppb (1.0,6.0; 0.5,9.5)) and in 8 (7%) they remained identical. In none of the children the change in FENO was larger than one standard deviation of the baseline mean. There was no association between % difference of FENO after MDP challenge and levels of baseline FENO (\( p = 0.68 \)), doctor diagnosed asthma (\( p = 0.93 \)) or presence of atopy.

Table 2. Levels of FENO at baseline and after mannitol dry powder challenge.

|                      | FENO at baseline | FENO after MDP challenge |
|----------------------|------------------|--------------------------|
|                      | N    | Median | IQR     | Median | IQR     | p-value |
| All children         | 107  | 18.5   | 10.5–45.5 | 16.5   | 8.5–40.5 | <0.001  |
| Doctor diagnosis of asthma |      |        |          |        |         |         |
| No                   | 43   | 14.5   | 8.0–22.5 | 12.0   | 6.5–20.0 | <0.001  |
| Yes                  | 64   | 26.0   | 12.5–63.0 | 23.3   | 10.3–56.8 | <0.001  |
| Atopy                |      |        |          |        |         |         |
| No (negative SPT)    | 18   | 8.0    | 5.5–14.5 | 6.8    | 5.0–12.0 | 0.006   |
| Mild (1 to 2 positive SPT) | 39 | 22.0   | 12.5–49.0  | 19.0   | 10.5–43.5 | <0.001  |
| Moderate (≥3 positive SPT) | 50 | 21.3   | 12.5–56.5  | 21.3   | 9.5–46.5 | <0.001  |
| BHR severity (MDP challenge)* |      |        |          |        |         |         |
| Normal (>635 mg, 11 manoeuvres) | 76 | 14.0   | 9.3–22.3 | 12.3   | 7.3–20.8 | <0.001  |
| Mild (155–635 mg, 8–10 manoeuvres) | 16 | 42.5   | 25.0–71.3 | 35.5   | 17.0–67.8 | 0.005   |
| Moderate to severe (<155 mg, ≤7 manoeuvres) | 15 | 65.0   | 40.5–122.5 | 64.5   | 46.5–102.5 | 0.079 |

Abbreviations: SPT, skin prick test; BHR, bronchial hyperresponsiveness; MDP, mannitol dry powder; FENO, fractional exhaled nitric oxide; IQR, interquartile range.

* BHR reported as MDP challenge results (provocative dose (in mg) inducing a 15% drop of FEV1 (PD15)). BHR severity is directly correlated with No of MDP manoeuvres.

Non-parametric test, matched group = Wilcoxon signed rank test comparing medians of FENO at baseline and after MDP challenge.

Figure 1. % difference of FENO after MDP challenge by baseline FENO, asthma, atopy and BHR severity. Abbreviations: FENO, fractional exhaled nitric oxide; MDP, mannitol dry powder; BHR, bronchial hyperresponsiveness; SPT, skin prick test. Baseline FENO defined as tertiles (low levels: <13 ppb; medium levels: 13 ppb–30 ppb; high levels: >30 ppb). Atopy defined as none (negative SPT), mild (1 to 2 positive SPT), moderate (≥3 positive SPT). BHR reported as MDP challenge results (provocative dose (in mg) inducing a 15% drop of FEV1 (PD15)) and defined as normal (>635 mg, 11 manoeuvres), mild (155–635 mg, 8–10 manoeuvres), moderate to severe (<155 mg, ≤7 manoeuvres).
of atopy ($p = 0.84$; Figure 1). However, the difference tended to be smaller in children who had moderate to severe BHR compared to those with normal BHR ($p = 0.08$; Figure 1).

**Discussion**

This study showed that FENO levels are indeed slightly reduced after a MDP challenge, compared to baseline. The differences, although statistically significant, were however small and unlikely to affect clinical decisions relating to diagnosis or treatment.

Results were unaffected by baseline FENO levels, the presence of atopy or doctor diagnosed asthma. However, the decrease was larger in children with normal MDP challenge who had performed more MDP manoeuvres (11) compared to those with moderate to severe BHR with less MDP manoeuvres ($\leq 7$). This suggests that the increased ventilation associated with repeated MDP manoeuvres and associated spirometries might have caused the decrease. The median decrease ($-2.5$ ppb, IQR $-7.0$, $-0.5$) was comparable to a bit larger than the decrease reported for spirometry alone [3,4], but smaller than the decrease reported for exercise tests ($-5$ ppb, from $-23.3$ ppb to $-18.5$ ppb) [13].

To our knowledge, this is the first study comparing FENO levels before and after MDP challenges. It includes a large number of children (107) and the clinical setting guarantees that results are representative for patients referred to respiratory outpatient clinics for potential reactive airways disease. Because most children were atopic and the majority diagnosed with asthma, results should not be extrapolated to healthy non-atopic children.

In conclusion, this study provides further support for the recommendation that FENO measurements in children, as a rule, should preferably be performed before spirometry and before bronchial provocation testing. This is particularly true for research. However, as the differences are small and clinically barely relevant, FENO measurements can still be interpreted even if performed after a MDP challenge test.

**Acknowledgments**

We thank all lab technicians of the pulmonology department in the children’s hospitals in Basel and St. Gallen for their assistance in our study. We also thank Parvinder Singh for formatting the manuscript.

**Author Contributions**

Editing and review of the manuscript: JB MPS DT BS JH CEK. Conceived and designed the experiments: JB DT JH CEK. Performed the experiments: JB DT BS JH. Analyzed the data: MPS CEK. Contributed reagents/materials/analysis tools: JB. Wrote the paper: JB MPS CEK.

**References**

1. British Thoracic Society Scottish Intercollegiate Guidelines N (2008) British Guideline on the Management of Asthma. Thorax 63 Suppl 4: iv1–121.
2. Silverman M, Anderson SD (1972) Standardization of exercise tests in asthmatic children. Arch Dis Child 47: 882–889.
3. Avital A, Springer C, Bar-Yishay E, Godfrey S (1995) Adenosine, methacholine, and exercise challenges in children with asthma or paediatric chronic obstructive pulmonary disease. Thorax 50: 511–516.
4. Anderson SD, Brannam J, Spring J, Spalding N, Rodwell LT, et al. (1997) A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med 156: 758–765.
5. Brannam JD, Anderson SD, Perry CP, Freed-Martens L, Lassig AR, et al. (2005) The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline. Respir Res 6: 144.
6. Barben J, Roberts M, Chew N, Carlin JB, Robertson CF (2003) Repeatability of bronchial responsiveness to mannitol dry powder in children with asthma. Pediatr Pulmonol 36: 490–494.
7. Barben J, Kuehni CE, Strippoli MP, Schiller B, Hammer J, et al. (2011) Mannitol dry powder challenge in comparison with exercise testing in children. Pediatr Pulmonol 46: 842–848.
8. Kersten ET, Driessen JM, van der Berg JG, Thio BJ (2009) Mannitol and exercise challenge tests in asthmatic children. Pediatr Pulmonol 44: 633–661.
9. Subbarao P, Brannam JD, Ho B, Anderson SD, Chan HK, et al. (2000) Inhaled mannitol identifies methacholine-responsive children with active asthma. Pediatr Pulmonol 29: 291–298.
10. Decimo F, Capristo C, Amelio R, Maieilo N, Capristo AF, et al. (2011) Evaluation of bronchial hyperreactivity with mannitol dry powder challenge test in a paediatric population with intermittent allergic asthma or allergic rhinitis. Int J Immunopathol Pharmacol 24: 1069–1074.
11. Taylor DR, Pijnenburg MW, Smith AD, De Jongste JC (2006) Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 61: 817–827.
12. American Thoracic S, European Respiratory S (2005) ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 171: 912–930.
13. Barreto M, Villa MP, Montesano M, Rennerova Z, Monti F, et al. (2006) Reduced exhaled nitric oxide in children after testing of maximal expiratory pressures. Pediatr Pulmonol 41: 141–145.
14. Gabriele C, Pijnenburg MW, Monti F, Hop W, Bakker ME, et al. (2005) The effect of spirometry and exercise on exhaled nitric oxide in asthmatic children. Pediatr Allergy Immunol 16: 243–247.
15. Mnzies D, Nair A, Lipworth BJ (2007) Portable exhaled nitric oxide measurement: Comparison with the "gold standard" technique. Chest 131: 410–414.
16. Schiller B, Hammer J, Barben J, Trachsel D (2009) Comparability of a handheld nitric oxide analyser with online and offline chemiluminescence-based nitric oxide measurement. Pediatr Allergy Immunol 20: 679–685.
17. Braun-Fahrlander C, Wuthrich B, Gassner M, Grize L, Neu U, et al. (1999) Prevalence and risk factors of allergic sensitization in Swiss school children. Allergology 22: 54–64.